Objective: Since 2021, the MiniMed™ 780G advanced hybrid closed-loop system with the non-adjunctive Guardian™ 4 sensor, that does not require calibration, has been commercially available in Europe. In this study, the real-world glycemic outcomes of the first 1,570 individuals using the system were evaluated.

Methods: Analyses were based on data collected since November 2021 from consenting users (N=1,570) in 15 countries who had ≥days of sensor glucose (SG) data. Glycemic outcomes including the mean±SD of the glucose management indicator [GMI], SG, and 24-hour and nighttime percentage of time spent within 70-180mg/dL (TIR) , at <54mg/dL [TBR54], <70mg/dL [TBR70] and >180mg/dL [TAR180] were determined. The mean±SD of time spent in closed loop and the number of closed-loop exits/week were also assessed.

Results: For 94±11% of time spent in closed loop, users had an SG of 153±18mg/dL, GMI of 6.96±0.41% and TIR of 73.5±10.7%. Their TBR54, TBR70 and TAR180 were 0.11±0.15%, 1.7±1.5% and 24.8±11.0%, respectively. During the night (12AM-6AM) , TIR was 81.5±12.8%, TBR54 was 0.08±0.20%, TBR70 was 1.1±1.7% and TAR180 was 17.5±12.9%. The number of closed-loop exits was 0.8±0.9/week.

Conclusion: MiniMed™ 780G system use with the Guardian™ 4 sensor involved substantial time in closed loop and favorable glycemic control that aligned with the recommended international consensus for continuous glucose monitoring metrics.


J.Shin: Employee; Medtronic. A.Arrieta: Employee; Medtronic. J.Castañeda: Employee; Medtronic. T.L.Cordero: Employee; Medtronic, Medtronic. A.S.Rhinehart: Employee; Medtronic, Stock/Shareholder; Medtronic. R.A.Vigersky: Employee; Medtronic.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.